摘要:[1]Simon, S. M., Schindler, M., Cell biological mechanisms of multidrug resistance in tumors, Proc. Natl. Acad. Sci. USA, 1994, 91: 3497.[2]Ambudkar, S. V., Dey, S., Hrycyna, C. A. et al., Biochemical, cellular, and pharmacological aspects of the multidrug trans-porter, Annu. Rev. Pharmacol. Toxicol., 1999, 39: 361.[3]Dudeja, P. K., Anderson, K. M., Harris, J. S. et al., Reversal of multidrug resistance phenotype by surfactants: Relationship to membrane lipid fluidity, Arch. Biochem. Biophys., 1995, 319 (1): 8309.[4]Collins, J. M., Scott, R. B., Grogan, W. M., Plasma membrane fluidity gradients of human peripheral blood leukocytes, J. Cell Physiol., 1990, 144: 42.[5]Collins, J. M., Dominey, R. N., Grogan, W. M., Shape of the fluidity gradient in the plasma membrane of living Hela cells, J. Lipid Res., 1990, 31: 261.[6]Ashman, R. F., Peckham, D., Alhasan, S. et al., Membrane unpacking and the rapid disposal of apoptotic cells, Immunol. Lett., 1995, 48(3): 159.[7]Sentjurc, M., Zorec, M., Cemazar, M. et al., Effect of vinblastine on cell membrane fluidity in vinblastine-sensitive and -resistant HeLa cells, Cancer Lett., 1998, 130(1-2):183.[8]Regev, R., Assaraf, Y. G., Eytan, G. D. et al., Membrane fluidization by ether, other anesthetics, and certain agents abolish-es P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells, Eur. J. Biochem., 1999, 259(1-2): 18.[9]Robert, A. S., Mariamme, S., Katherine, L. S., Altered lipid packing identifies apoptotic thymocytes, Immunol. Lett., 1993, 36: 283.[10] Lagerberg, J. W., Kallen, K. J., Haest, C. W. et al., Factors affecting the amount and the mode of merocyanine 540 binding to the membrane of human erythrocytes, Biochim. Biophys. Acta, 1995, 1235(2): 428.[11] Stillwell, W., Wassall, S. R., Dumaual, A. C. et al., Use of merocyanine (MC540) in quantifying lipid domains and pack-ing in phospholipid vesicles and tumor cells, Biochem. Biophys. Acta, 1993, 1146(1): 136.[12] Howlett, N. G., Avery, S. V., Relationship between cadmium sensitivity and degree of plasma membrane fatty acid unsatu-ration in Saccharomyces cerevisiae, Appl. Microbiol. Biotechnol., 1997, 48(4): 539.[13] Petriz, J., Oconnor, J. E., Carmona, M. et al., Is Rhodamine-123 an appropriate fluorescent probe to assess P-glycoprotein mediated multidrug resistance in vinblastine-resistant CHO cells? Analytical Cellular Pathology, 1997, 14(3): 129.[14] Leonce, S., Burbridge, M., Flow cytometry: a useful technique in the study of multidrug resistance, J. Bio. Cell, 1993, 78(1-2): 63.[15] Le Moyec, L., Tatoud, R., Degorges, A. et al., Proton nuclear magnetic resonance spectroscopy reveals cellular lipids in-volved in resistance to Adriamycin and Taxol by the K562 Leukemia cell line, Cancer Res., 1996, 56: 3461.[16] Callaghan, R., Stafford, A., Epand, R. M., Increased accumulation of drugs in a multidrug resistant cell line by alteration of membrane biophysical properties, Biochim. Biophys. Acta, 1993, 1175(3): 277.[17] Sinicrope, F. A., Dudeia, P. K., Bissommette, B. M. et al., Modulation of P-glycoprotein-mediated drug transport by al-terations in lipid fluidity of rat liver canlicular membrane vesicles, J. Biol. Chem., 1992, 267(35): 24995.[18] Romsicki, Y., Sharom, F. J., The membrane lipid environment modulates drug interactions with the P-glycoprotein multi-drug transporter, Biochemistry, 1999, 38(21): 6887.[19] Garel, O., Lecureur, V., Guillouzo, A., The P-glycoprotein multidrug transporter, Gen. Pharmacol., 1996, 27(8): 1283.[20] Aran, J. M., Pastan, I., Gottesman, M. M., Therapeutic strategies involving the multidrug resistance phenotype: the MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy, Adv. Pharmacol., 1999, 46: 1.[21] Zaman, G. J., Flens, M. J., Vanleusden, M. R. et al., The human multidrug resistance-associated protein (MRP) is a plasma membrane drug efflux pump, Proc. Natl. Acad. Sci. USA, 1994, 91(19): 8822.[22] Gately, D. P., Howell, S. B., Cellular accumulation of the anticancer agent cisplatin: a review, Br. J. Cancer, 1993, 67: 1171.